Japanese Pediatric Leukemia/Lymphoma Study Group Prospective observational study of relapsed/refractory pediatric acute myeloid leukemia

Japanese Pediatric Leukemia/Lymphoma Study Group Prospective observational study of relapsed/refractory pediatric acute myeloid leukemia - JPLSG-AML-R15

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031734

Enrollment

160

Registered

2018-06-01

Start date

2018-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/refractory acute myeloid leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children aged <18 years diagnosed with acute myeloid leukemia and relapsed aged <25 years Children aged <18 years diagnosed with primary induction failure

Exclusion criteria

Exclusion criteria: Additional or multiple relapsed patients Patients with secondary acute myeloid leukemia

Design outcomes

Primary

Measure	Time frame
3-year overall, event-free, and progression-free survival after diagnosis of relapsed/refractory acute myeloid leukemia 3-year overall, event-free, and progression-free survival after hematopoietic stem cell transplantation	—

Countries

Japan

Contacts

Public ContactHIroshi Moritake

University of Miyazaki Division of Pediatrics

hiroshi_moritake@med.miyazaki-u.ac.jp0985-85-0989

Outcome results